Clinuvel Pharmaceuticals Limited
CUVLHealthcareNASDAQBiotechnology · Last scanned Oct 26, 2026
Scan Results
Daily timeframeClinuvel Pharmaceuticals Limited, a biopharmaceutical company, focuses on developing and delivering therapies for patients with genetic, metabolic, and dermatological disorders in Australia, Ireland,. At a $249.4M market cap, Clinuvel Pharmaceuticals Limited ranks as a micro-cap company within healthcare. Its lead drug candidate is SCENESSE, a systemic photoprotective drug for the prevention of phototoxicity in adult patients with erythropoietic protoporphyria (EPP).
Market Cap
$249.4M
Beta
0.58
P/E (TTM)
10.98
P/E (Fwd)
—
EPS (TTM)
$0.45
EPS (Fwd)
—
ROE
13.2%
ROA
8.9%
Cash
$252.1M
Total Debt
$1.9M
Free CF
$25.4M
52W Change
-32.9%
Annual Financials
Cash vs Debt
Where CUVL stands vs its 150-day and 200-day moving averages
As of the October 19, 2026 close, CUVL finished 20.49% below its 150-day moving average ($6.59) and 24.17% below its 200-day moving average ($6.91). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is CUVL overbought or oversold?
At the October 19, 2026 close, CUVL's RSI(14) was 38.9, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
Clinuvel Pharmaceuticals Limited holds $252.1M in cash against $1.9M in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. The company generates $25.4M in free cash flow annually, which funds everything from R&D to shareholder returns without needing external financing. Return on equity stands at 13.2%, which is decent for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. An ROA of 8.9% suggests reasonable efficiency in deploying the company's asset base. Revenue has grown from $78.3M (2023) to $94.0M (2026), reflecting a 20% increase over the period.
The relatively low beta of 0.58 suggests CUVL is a less volatile holding compared to the broader index. With cash comfortably exceeding debt, CUVL has financial flexibility that may help navigate uncertain periods. No single metric tells the full story. Reviewing CUVL's risk profile alongside its fundamentals and technical indicators provides a more complete picture.